Hospital News and Research

RSS

FDA approves key testing phase for artificial pancreas

A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.

19 Mar 2012

BSD-500 Hyperthermia System installed at Fort Belvoir Community Hospital

BSD Medical Corporation announced today the purchase, installation and acceptance of a BSD-500 Hyperthermia System (BSD-500) by Fort Belvoir Community Hospital (Fort Belvoir).

19 Mar 2012

Improvements in trauma care could save two million lives

Up to two million lives, annually, could be saved globally with improvements in trauma care, particularly in low- and middle-income countries. This estimate by Charles Mock, from the University of Washington in Seattle, and his team provides support for investment in and greater attention to strengthening trauma care services globally. Their work is published online in Springer's World Journal of Surgery.

19 Mar 2012

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

Ventana launches novel platform for special stains

Ventana Medical Systems, Inc., a member of the Roche Group, is now introducing a novel platform for special stains, built on its industry-leading VENTANA BenchMark technology.

19 Mar 2012

Study confirms value of Cambridge Heart's MTWA test for SCA

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that a new study published on-line in the Heart Rhythm Journal confirms the value of Microvolt T-Wave Alternans (MTWA) testing for identifying patients at risk of sudden cardiac arrest.

19 Mar 2012

First Edition: March 19, 2012

Today's headlines reflect the anticipation and anxiety that surrounds the Supreme Court's upcoming health law oral arguments.

19 Mar 2012

IOB, Delcath to launch CHEMOSAT system for Spanish cancer patients

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT Delivery system with the Instituto Oncologico Baselga (IOB), Grupo Quiron—a private hospital located in Barcelona, Spain.

19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

East Asian BIM gene variant contributes to drug resistance in cancer

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.

19 Mar 2012

Scientist generates mutant version of IL-2 protein to treat advanced cancers

The utility of a naturally occurring protein given, sometimes to great effect, as a drug to treat advanced cancers is limited by the severe side effects it sometimes causes. But a Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.

19 Mar 2012

Pfizer supports First World Congress on Healthy and Active Ageing

As an official partner of the First World Congress on Healthy Ageing, Pfizer reaffirms the company's commitment to promote healthy and active ageing at all stages of life as a basis for enhanced productivity in the Asia Pacific. Pfizer will lead a luncheon symposium today focused on the relationship between health and economic sustainability and the resulting challenges and opportunities of shifting demographics across the region.

19 Mar 2012

Westmead Hospital endorse a new medical device designed to increase blood circulation and prevent Deep Vein Thrombosis

A new medical device, the geko™, designed to increase blood circulation through neuromuscular electro–stimulation to the common peroneal nerve, has received the positive endorsement of Westmead Hospital, New South Wales, as an important new development in the prevention of Deep Vein Thrombosis (DVT).

18 Mar 2012

Tiny Tim may have suffered from rickets and TB

Le Bonheur Professor Russell Chesney, M.D. believes he knows what was ailing Tiny Tim, the iconic character from Charles Dickens' "A Christmas Carol." Based on detailed descriptions of both the symptoms and living conditions of 18th century London, Dr. Chesney hypothesizes that Tiny Tim suffered from a combination of rickets and tuberculosis (TB).

17 Mar 2012

HemCon disappointed with CAFC decision over Marine Polymer patent infringement case

HemCon Medical Technologies, Inc. announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued an en banc decision on March 15, 2012 in the 2006 patent infringement case brought by Marine Polymer Technologies Inc. The decision affirmed a trial court decision awarding damages to Marine Polymer and enjoining the manufacture of infringing products.

17 Mar 2012

Researchers report higher price tag for robotic prostatectomy surgery

In perfecting the science of medicine, advancements always face exhaustive scrutiny and opposition. Typically, these rigors focus on confirming the efficacy of a procedure or treatment to ensure it remains in the patient's best interest for healing or wellness. More recently, with heightened emphasis on government-funded healthcare, medical procedures such as robotic prostatectomy surgery for prostate cancer treatment are under fire for cost.

17 Mar 2012

Clinicians to discuss best approaches for future cancer treatment at Brainlab's radiotherapy meeting

Today clinicians from around the world will gather at the 4th Brainlab European Radiotherapy User Meeting to share their best practice and experiences in treating difficult-to-treat cancers using advanced radiotherapy.

17 Mar 2012

Ethisphere Institute recognizes HCA among 2012 World's Most Ethical Companies

Hospital Corporation of America which has 163 hospitals and 111 ambulatory surgery centers in 20 states and London, England, has been recognized by the Ethisphere Institute as one of the 2012 World's Most Ethical Companies.

17 Mar 2012

ApolloMed signs service agreement with Care1st

Apollo Medical Holdings, Inc., a leading provider of hospitalist, critical care and integrated medical management services in California, today announced that ApolloMed Hospitalists, one of its affiliated medical groups, signed a service agreement with Care1st Health Plan to provide inpatient care services to its members at 15 hospitals throughout Los Angeles County.

17 Mar 2012